Patient Resources / Clinical Trials
ImmusanT is advancing the development of their lead product, Nexvax2®, which is a therapeutic vaccine designed to protect against the effects of gluten exposure while patients maintain a gluten-free diet. For the Nexvax2® therapy, ImmusanT has successfully established cGMP drug manufacturing, pharmacokinetics and toxicology studies, and preclinical proof-of-concept in a transgenic mouse model. In addition, ImmusanT has completed multiple Phase 1 clinical trials demonstrating that Nexvax2® is well tolerated, safe, and has relevant bioactivity in human subjects.
In multiple Phase 1 trials, Nexvax2® was demonstrated to be safe and tolerable at therapeutically-relevant dose levels.
A Phase 2 trial evaluating the safety and efficacy of Nexvax2® as a method to protect patients against the effects of gluten exposure while patients maintain a gluten-free diet is ongoing. This trial, RESET CeD, intends to enroll approximately 150 patients across the United States, Australia and New Zealand.
For more information on RESET CeD, the Phase 2 clinical trial of Nexvax2 in celiac disease, please click here. To discuss your eligibility to participate, contact one of the sites in your area.
Type 1 Diabetes
ImmusanT has completed discovery work investigating the relationship between Celiac Disease and Type 1 Diabetes at the Joslin Diabetes Center.
If you are interested in learning more about ImmusanT-sponsored clinical trials, please visit our Learn More page.